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The discovery of mutations causing human disease has so far been biased toward protein-coding regions. Having excluded all annotated
coding regions, we performed targeted massively parallel resequencing of the nonrepetitive genomic linkage interval at Xq28 of family
MRX3.We identified in the binding site of transcription factor YY1 a regulatory mutation that leads to overexpression of the chromatin-
associated transcriptional regulatorHCFC1. When tested on embryonic murine neural stem cells and embryonic hippocampal neurons,
HCFC1 overexpression led to a significant increase of the production of astrocytes and a considerable reduction in neurite growth. Two
other nonsynonymous, potentially deleterious changes have been identified by X-exome sequencing in individuals with intellectual
disability, implicating HCFC1 in normal brain function.Intellectual disability is one of the most genetically hetero-
geneous human disorders.1 Among these, X-chromosome-
linked intellectual disability (XLID) has been the best
characterized at >92 genes involved.2 Recent large-scale
X-exome resequencing3 complemented by high-resolution
copy-number profiling4 failed to provide imminent
answers for >50% of 208 families studied. Both studies
used exome-centric and thus coding-sequence-biased
mutation searches. Currently, about 86% of ~100,000
known mutations causing human disease reside in the
coding sequences.5 Noncoding variants are frequently
overlooked or deemed too hard to be investigated. How-
ever, the advent of more systematic whole-genome
sequencing,6 together with constantly improving annota-
tion of the human genome (ENCODE), is facilitatingmuta-
tion inquiry also into the noncoding and regulatory
sequences.
MRX3 is a family of northern European descent and is
affected by nonsyndromic intellectual disability (MIM
309541), which was mapped to Xq28-qter in 1991.7 The
affected males in the MRX3 family are generally facially
nondysmorphic; a few of the males have been described
as having subtle dysmorphism, such as a small chin,
high arched palate, or tapered fingers, but no feature is
consistent throughout the family. Body habitus is normal
and consists of below-average height (<3rd to 25th percen-
tile) and a head shape that is often brachycephalic and
of variable size (5th to 97th percentile). Affected males func-
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with supervised employment, whereas others need full-
time supervision. Many of the males show behavioral
problems, including aggression, and are not easily
managed. In addition, others are described as reclusive
and display a number of autistic symptoms, including
ritualized and obsessive behaviors, narrow interests, and
little socialization. Only one of the affected males (V-14
in Figure S1, available online; now deceased) has been
described as having psychotic symptoms. One male
(VII-7 in Figure S1), who had absence seizures during child-
hood, has normal cerebral imaging. No other affected
males have epilepsy or have had brain imaging. Obligate
carrier females appear to be normal and show high
(>96%) skewing of their X inactivation, as measured
on white blood cells (data not shown). This study was
approved by the Women’s and Children’s Health Network
Human Research Ethics Committee, and informed consent
was obtained from all participants.
The 5.6 Mb linkage interval of the MRX3 family is
known to be rich in genes8 and harbors 108 protein-coding
genes (Figure 1A), accounting for ~2.42% of the whole
sequence in the interval. For over 20 years, extensive
studies, including the most recent large-scale ap-
proaches,3,4 have failed to identify the causative mutation.
In the presence of solid genetic evidence for X chromo-
some involvement, we hypothesized that the mutation
might reside outside the coding region. To identify poten-
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Figure 1. Sequencing, Mapping, and Identification of the chrX:152,890,455A>G Variant in a Core YY1 Binding Site of the HCFC1
Regulatory Region
(A) The upper panel shows targeted resequencing of the linkage interval in Xq28, an overview of the X chromosome, and custom tracks
representing sequence-coverage histograms and tiled regions. The 108 genes in the region are displayed in the UCSC genome browser
(hg18). The tiled region (~5.5Mb) on the capture array includes all exons fromGenBank,mRNA and all ESTs, putativeminimal promoter
regions 2,000 bp upstream of the first exon in GenBank mRNAs, all snoRNAs, and miRNAs. The lower panel shows an overview of the
genomic structure of HCFC1 and the sequence-coverage histograms.
(B) Partial sequence chromatograms showing the chrX:152,890,455A>G variant in the YY1 consensus DNA-binding site (BS; shown
below) in a control male (WT), an affected male from the MRX3 family (MT), and a carrier female (carrier).
(C) Comparison of the sequences harboring the chrX:152,890,455A>G variant across 18 vertebrate species. The chrX:152,890,455A
sequence is localized in the intergenic region between HCFC1 and TMEM187. The core motif (CCAT) of the YY1 binding site is
highlighted with an arrowhead pointing at the chrX:152,890,455A nucleotide.
(D) Schematic of the partial genomic structure around the 50 ends of HCFC1 and TMEM187. There are six predicted YY1 binding sites
(marked as S1–S6) in the region. The arrows show the direction of HCFC1 transcription and the transcription start sites (TSSs) associated
with reference sequence NM_005334.2. The new TSS was extended beyond the S2 YY1 binding site with the use of ESTs and other
publicly available resources (ENCODE and DBTSS). The sequence of the chrX:152,890,455A>G variant is located within the S2 YY1
binding site. The hatched region indicates the 50 UTR, whereas the solid box indicates the HCFC1 open reading frame.array targeted to all coding regions and putative functional
noncoding regions in the linkage interval (Figure 1A).
Genomic DNA from individual V-4 in the MRX3 family7
was enriched to an estimated mean of 1,4163 (Figure S1
and data not shown). The captured DNA fragments were
sequenced with the Illumina GAIIx massively parallel
sequencing platform, and 4.78 3 106 65 bp reads (51.64%
of the total number of reads) mapped to a repeat-masked,
human genome reference sequence from UCSC (hg18) as
described previously9 and covered 1.293 106 bp of uniqueThe Americsequences in the linkage interval (Figures S2 and S3).
Combined with our previous X-exome Sanger sequenc-
ing data,3 only 356 bp (<0.25% of the coding region
from the linkage interval) distributed over four genes
showed zero coverage (Tables S1 and S2). These zero-
coverage coding regions (which included the first exon
of SLC6A8 [MIM 300036], a gene which has been shown
to be mutated in XLID) were sequenced manually and
were excluded from having DNA sequence variation in
the MRX3 family.an Journal of Human Genetics 91, 694–702, October 5, 2012 695
In total, 383 genetic variants were called. We prioritized
variants not present in dbSNP130 for further analysis
(Figure S3). This prioritization identified 15 unique non-
coding variants. We found no unique sequence variants
(synonymous or nonsynonymous) in the protein-coding
regions. Among the 15 unique noncoding variants, only
the chrX:152,890,455A>G variant (UCSC hg18) is highly
conserved (Table S3). This variant lies within the intergenic
region between host cell factor C1 (HCFC1 or HCF-1 [MIM
300019]) and TMEM187 (or CXorf12 [MIM 300059]).
Subsequently, we found that the chrX:152,890,455A>G
variant localizes in a putative binding site for the transcrip-
tion factor Yin-Yang-1 (YY1) (Figures 1B–1D). A recent
study reported a de novo YY1 (MIM 600013) mutation
as a plausible cause of intellectual disability.10 With
TFSEARCH,11 the variant was predicted to abolish YY1
binding. Other variants were weakly conserved or poorly
annotated and were not investigated for functional
effect(s). There are six YY1 binding sites (S1–S6) in the
same orientation in the region between HCFC1 and
TMEM18712 (Figure 1D). We postulated that HCFC1 is the
most likely affected gene. The S2 chrX:152,890,455A>G
variant completely segregated with intellectual disability
in the original and extended MRX3 pedigrees (Figure S1).
According to the HCFC1 reference sequence,
NM_005334.2, the S2 chrX:152,890,455A>G variant
would be in the intergenic region. However, our analysis
of human expressed sequence tags (ESTs) and other
publicly available resources (e.g., ENCODE and DBTSS)
strongly suggests that the predominant HCFC1 transcrip-
tion start site (TSS) is 450 bp upstream of NM_005334.2
at chrX: 152,890,463 (see Figure 2D) This makes the
chrX:152,890,455A>G variant (and the S2 YY1 binding
site) part of the HCFC1 50 UTR, only ~8 bp from the TSS
of HCFC1 (Figures 1D and 2D).
To assess the impact of the S2 chrX:152,890,455A>G
variant on HCFC1 expression, we tested the relative levels
of total HCFC1 transcripts by using quantitative RT-PCR
(qRT-PCR). The HCFC1 mRNA expression in affected
individuals’ (n ¼ 2) lymphoblastoid cell lines (LCLs)
was >1.63 higher (p < 0.006, Student’s one-tailed t test)
than that in male and female controls (Figure 2A and
Figures S4–S6). Given that HCFC1 is duplicated in the
majority of individuals with MECP2 (MIM 300005) dupli-
cations, we also tested HCFC1 expression in cell lines of
these affected individuals (Figure 2A and data not shown).
No significant difference in HCFC1 expression was identi-
fied, suggesting that HCFC1 is not upregulated when
duplicated. This also suggested to us that the YY1 binding
site at position S2 is a repressive cis-regulator rather
than an enhancer.12 We also tested the possibility that S2
could function as a remote cis-regulatory sequence for
neighboring genes, namely TMEM187 and, more distantly,
RENBP (MIM 312420)20 and MECP2.21 The expression of
TMEM187 is highly variable and not responsive to S2 vari-
ation in the affected individuals from the MRX3 family.
Although RENBP expression is significantly (2-fold) upre-696 The American Journal of Human Genetics 91, 694–702, Octobergulated in individuals with MECP2 duplications, it is
only slightly upregulated in the affected individuals
from the MRX3 family. MECP2 expression is higher in
the affected individuals from the MRX3 family, but
this was not statistically significant (Figure 2A and Fig-
ure S4). We therefore concluded that HCFC1 is likely
to be the only gene significantly affected by the S2
chrX:152,890,455A>G variant in the YY1 binding site.
To further investigate whether the chrX:
152,890,455A>G variant has a functional effect, we per-
formed an electrophoretic mobility shift assay (EMSA) by
using the nuclear extracts from human embryonic kidney
(HEK) 293T cells. The presence of the variant completely
abolished YY1 binding (Figure 2B). This was supported
by chromatin immunoprecipitation with a YY1 antibody
in LCLs from affected individuals from the MRX3 family
(Figure 2C). To study the effect of the S2 YY1 binding site
on HCFC1 expression and explore the activity of the other
neighboring YY1 binding sites, we generated wild-type and
mutant S2 luciferase reporter constructs with different
lengths of the HCFC1 and TMEM187 UTRs and intergenic
regions (Figure 2D). The construct containing S1, S2, and
S3 was the only one significantly impacted by the S2
chrX:152,890,455A>G variant (Figure 2D).
That HCFC1 is highly expressed during embryonic brain
development20 (Figure S7) led us to investigate the effect
that HCFC1 overexpression has on the behavior of embry-
onic murine neural cells, namely neural stem cells (NSCs)
and embryonic hippocampal neurons. We employed
nucleofection to deliver expression plasmids encoding
enhanced green fluorescent protein (EGFP) and either an
empty-vector control or a HCFC1 expression plasmid
into ex-vivo cultures of these neural populations, resulting
in cotransfection of 30%–40% of cells (data not shown). In
NSCs grown nonadherently (i.e., as neurospheres), overex-
pression of HCFC1 slightly reduced the proliferation of the
entire culture (Figure 3A). To resolve further, we used the
5-ethynyl-20-deoxyuridine (EdU) pulse label assay to iden-
tify cells in S phase (i.e., proliferative cells). To restrict anal-
ysis to only transfected cells (i.e., those expressing EGFP),
we employed either fluorescent-activated cell sorting
(FACS) or immunofluorescent microscopy. Overexpres-
sion of HCFC1 resulted in a significant reduction in the
percentage of EdU-labeled cells (~11% lower than controls)
grown nonadherently (Figure 3B), whereas under adherent
culture conditions more permissive to differentiation, the
percentage of EdU-labeled cells was even further reduced
(~28% lower than controls) (Figure 3C and Figure S8).
Because analysis of the cell-cycle length revealed no sig-
nificant difference (Figure 3D), we explored the possibility
that HCFC1 overexpression might instead promote cell-
cycle exit. We used immunofluorescent microscopy to
quantify the differentiation status of transfected cells.
The overexpression of HCFC1 significantly increased the
production of astrocytes (~30% higher than controls),
whereas the percentages of neurons and oligodendrocytes
were unaffected (Figures 3E and 3F and Figure S8). Next,5, 2012
Figure 2. The chrX:152890455A>G Variant Leads to Upregulation of HCFC1mRNA Expression through Loss of the YY1 Binding Site
within Region S2
(A) qRT-PCR results show that affectedMRX3 familymembers (n¼ 2) have significantlymore upregulation ofHCFC1 expression in LCLs
than do controls (n ¼ 4 for females and n ¼ 4 for males) (p < 0.006 for MRX3 males against all controls) and individuals with MECP2
duplications (n ¼ 3). Relative expression normalized against the ACTB mRNA is shown for HCFC1, MECP2, and YY1. qRT-PCR was
performed as previously described13 with primers listed in Table S4. Error bars represent5 standard error of the mean (SEM).
(B) An electrophoretic mobility shift assay (EMSA) shows that the chrX:152,890,455A>G variant of S2 (mS2) abolishes YY1 binding. IgG
is the unrelated rabbit IgG. Unlabelled probes are 253, 1003, and 5003 higher than labeled probes. The positions of the YY1 shift and
YY1 supershift (antibody from Santa Cruz; sc-7341X) are indicated by arrows. Isolation of nuclear extracts and EMSA was performed as
previously described14,15 with oligonucleotide probes listed in Table S5.
(C) The chrX:152,890,455A>G variant abolishes YY1 binding. A ChIP assay was performed on formaldehyde crosslinked LCL lysates
from normal (WT; n ¼ 2) and MRX3 (MT; n ¼ 2) males with the use of rabbit anti-YY1 antibody or control IgG as previously
described.16 The level of YY1 binding to the S2 region of HCFC1 was determined by semiquantitative PCR. The S6 YY1 binding site
and an unrelated region of DNA around HUWE1 were used as negative controls. All primers are listed in Table S6. Whereas the region
of S2 YY1 binding site shows a clear decrease of PCR product in the MRX3 males with respect to controls, this is not seen for a more
distant S6 YY1 binding site PCR. A decrease rather than a complete loss of S2 PCR products in the MRX3 male LCL lysates is most likely
due to immunoprecipitation of closely located YY1 binding sites (e.g., S1 and S3) rather than through the S2 site itself. Inputs (lanes
9–12) are equivalent to 1% of the immunoprecipitated samples (lanes 1–4 and 5–8).
(D) The left panel shows a schematic representation of the genomic structure of the 50 ends of HCFC1 and TMEM187 and the pGL4
constructs for luciferase reporter assays. The positions of the HCFC1 TSS (including the one associated with NM_005334.2, as well as
the new TSS site) and the TMEM187 TSS are indicated with UCSC hg18 coordinates and arrows. The positions of the YY1 S1–S6 sites
are indicatedwith respect to the newHCFC1 TSS at chrX:152,890,463. The S2 site is crosshatched. Each different-length reporter plasmid
has been made with wild-type (WT; A) and mutant (MT; G) nucleotides as follows: the 1,265 bp (chrX: 152,889,593152,890,857),
705 bp (chrX: 152,890,153–152,890,857), and R-705 bp (chrX: 152,890,153–152,890,857) fragments were amplified from genomic
DNAs of normal or affected individuals in MRX3 family with the use of primers listed in Table S7 and were cloned into pGEMT
(Promega). The 506 bp (chrX: 152,890,153–152,890,658) and 127 bp (chrX: 152,890,153–152,890,279) fragments were obtained
with restriction-enzyme digests with XhoI and HindIII (for the 506 bp fragment) and AvrII and HindIII (for the 127 bp fragment)
from pGEMT containing 705 bp inserts. All fragments were subsequently cloned into the multiple cloning site of the pGL4.1 luciferase
reporter (Promega). The arrows show the direction of transcription. The right panel shows the results of the corresponding luciferase
reporter assays conducted in HEK 293T cells as previously described.14 Values are normalized against the 705 bp wild-type construct.
Error bars represent standard deviation of at least three independent experiments. *p < 0.0007 by Student’s t test.
(E) Schematic of HCFC1 domain structure with the 53 Kelch domain region, the basic region (containing SIN3A17 and ZBTB1718 protein
interacting regions), HCF1 repeats, and the acidic region. The two unique variants identified as part of this study are underlined. The two
variants identified by Piton et al.19 are indicated by an asterisk (*), and those identified by Tarpey et al.3 are indicated by a number sign
(#). The values in brackets are PolyPhen 2 scores. The diagram is not drawn to scale.
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Figure 3. HCFC1 Overexpression Alters the Behavior of Embryonic Neural Cells
Ex vivo cultures of embryonic NSCs or embryonic hippocampal neurons were isolated and manipulated as previously described.22,23
Cells were transfected with plasmids expressing EGFP (pMAX-EGFP; Lonza) together with either an empty vector control (pcDNA3.1;
Invitrogen) or HCFC1 expression plasmid (pCGN-HCFC1). All experiments were done in biological triplicates. All graphs are the average
of triplicate experiments5 the standard deviation (error bars). *p < 0.05 by Student’s two-tailed t test.
(A) Proliferation of transfected NSC cultures grown in nonadherent conditions over 4 days was assessed with the Cell Titer96 AQueous
Cell Proliferation Assay as per the manufacturer’s (Promega) instructions. Note that only ~30% of the cells are transfected.
(B–C)HCFC1 overexpression reduces the number of NSCs in S phase. 5-ethynyl-20-deoxyuridine (EdU) labeling and detection were done
with the Click-it EdU AlexaFluor647-Azide kits (Invitrogen) as per the manufacturer’s instructions. In (B), EdU pulse labeling (6 hr) of
transfected NSCs in nonadherent culture was analyzed with FACS (FACS AriaII flow cytometer, BD Bioscience), and in (C), 12 hr pulse
labeling of transfected NSCs after 3 days of adherent culture was analyzed by immunofluorescent microscopy.
(D) HCFC1 overexpression does not alter the length of the NSC cycle. NSCs were synchronized in S phase with hydroxyurea (HU) and
were allowed to re-enter the cell cycle at the G2 phase in the presence of EdU, as previously described.24 Cell-cycle length is inferred by
the number of transfected cells that have transitioned through G2, M, G1, and back into S, which is reported by the number of cells
labeled by EdU at 0, 8, and 24 hr as previously described.24
(E–F) HCFC1 overexpression promotes differentiation of NSCs. In (E) are representative immunofluorescent images after 3 days of
adherent culture. Transfected cells were identified via EGFP expression (green), and their differentiation status was obtained with anti-
bodies against cell-type-specific marker proteins: GFAP was used for astrocytes (red), and CNPase was used for oligodendrocytes (cyan).
Nuclei were stained with DAPI (blue). The upper-panel arrowheads indicate unidentified transfected cells, and the lower-panel arrow-
heads indicate transfected cells of astrocyte identity. The quantification of cellular identities is shown in (F). At least 300 cells were
counted for each experiment (conducted in triplicate).
(G–H)HCFC1 overexpression reduces primary axonal outgrowth in hippocampal neurons. In (G) is a representative immunofluorescent
image of 4-day-old cultures. Transfected neurons were identified with GFP expression (green) and stained with antibodies specific for
axons (Tau1; cyan) and dendrites (MAP2; red). Nuclei were stainedwith DAPI (blue). In (H) is the quantification of primary axonal length
at days 4 and 8 of culture, conducted as previously described.23 All staining andmicroscopy were conducted as previously described.23,25we addressed the effect of HCFC1 overexpression on the
outgrowth of freshly isolated embryonic hippocampal
neurons. HCFC1 overexpression resulted in a significant
reduction in neurite growth as evidenced by a greater
than 50% reduction in primary axon growth at day 4 of698 The American Journal of Human Genetics 91, 694–702, Octoberculture and a 33% reduction at day 8 (Figures 3G and
3H). This result was coupled with reductions in the degree
of neurite arborization, as reported by the number of both
axonal and dendritic termini, and high amounts of neu-
ronal death (Figure S9). Together, these data strongly5, 2012
suggest that HCFC1 is a potent regulator of embryonic
neural development. Overexpression in NSCs promoted
cell-cycle exit coupled with astrocyte production, whereas
in neurons, overexpression hindered neurite growth and
viability.
The expression of the evolutionarily conserved tran-
scription regulator HCFC1 is tightly regulated by YY1,
which suggested to us that this is necessary to ensure
that HCFC1 target genes are also strictly regulated. To
investigate this further, we performed microarray expres-
sion profiling by using MRX3 (n ¼ 2) and control male
(n ¼ 4) and female (n ¼ 5) LCLs on HT-12v4 (WGDASL)
arrays (Illumina) (the NCBI Gene Expression Omnibus
accession number for array data is GSE39326).
Background-subtracted expression values were quantile
normalized with the lumi package from bioconductor.26
Significant differential expression on probes with a detec-
tion threshold> 0 was determined with the limma package
from bioconductor.27 We identified 218 significantly de-
regulated genes (p < 0.01; false discovery rate [FDR] < 0.8),
at least five of which have been identified by chro-
matin immunoprecipitation (ChIP) sequencing as targets
of HCFC128 (these five are MRPL34 [MIM 611840], LSG1
[MIM 610780], NDUFB5 [MIM 603841], MRPL47 [MIM
611852], and NDUFS7 [MIM 601825]). With the exception
of LSG1, all these genes are involved in mitochondrial
function or biogenesis, a process in which HCFC1 has
been previously implicated.29 Further analysis of the 218
genes identified a cluster of 24 genes whose products
localize to mitochondria and show significant enrichment
in this data set (p ¼ 0.0012 with medium classification
stringency on DAVID30). Significant enrichment was also
noted for genes and their acetylation-involved proteins,
which included those that bind to or directly acetylate
histones, consistent with the known function of HCFC1
as a chromatin-associated transcriptional regulator. Over-
all, the array results support HCFC1 upregulation due to
a mutation in the YY1 binding site as having an impact
on downstream regulation of gene expression. The biolog-
ical processes associated with known functions of HCFC1,
together with the neural functions reported in this study,
rank highly on functional-annotation tables of differen-
tially expressed genes (Tables S8–S10).
Finally, we identified two additional unique HCFC1
variants by using systematic X chromosome exome
sequencing of probands from unresolved families affected
by X-chromosome-linked or X-chromosome-suggestive
intellectual disability (Figures S10–S12 and Table S11;
unpublished data). These include c.674G>A (p.Ser225Asn)
(RefSeq accession number NM_005334.2) within one of
the Kelch domains and c.5267C>T (p.Ala1756Val) (RefSeq
NM_005334.2). We have also found a c.2626G>A
(p.Gly876Ser) variant, which lies within the ZBTB17/
GABP2 binding domain of HCFC1 and has been identified
in a frequency of 1/1,207 chromosomes (or 7/8,454;
National Heart, Lung, and Blood Institute [NHLBI]
Exome Variant Server). Variant p.Ser225Asn segregated inThe Americfamily D144 (Figure S11 and Table S11), and variant
p.Ala1756Val, as well as missense change c.356A>G
(p.Gln119Arg) (RefSeq NM_005096.3) in another gene,
ZMYM3 (MIM 300061), was found in the index affected
individual of a family with four affected males in two
generations (family D82, Table S11) but could not be
tested for cosegregation with XLID because DNA from
other family members was unavailable. The c.2626G>A
(p.Gly876Ser) variant was found in a simplex case who
had intellectual disability and whose mother had 100%
skewing of X inactivation (family D147; Table S11).
The X-exome sequencing of the affected individual
from family D147 also identified a potentially dele-
terious change (c.3101T>G [p.Phe1034Cys] [RefSeq
NM_005120.2]) in MED12 (MIM 300188), mutations in
which are known to cause XLID31 (MIM 305450 and
309520). No other obviously deleterious X-exome variants
were identified in these families, making involvement of
these HCFC1 variants plausible in at least families D144
and D82. Interestingly, Piton et al.19 identified several
uniqueHCFC1 variants, including p.Gly876Ser (annotated
as p.Gly779Ser19) in a male individual with autism
spectrum disorder and p.Thr239Met (annotated as
p.Thr142Met; not present in the Exome Variant Server
data) in a female individual with schizophrenia (Fig-
ure 2E). Tarpey et al.3 found two unique nonsynonymous
changes and a splice-site change (c.5379þ2T>C [RefSeq
NM_005334.2]) affecting the canonical 50 donor splice
site of intron 21. Inspection of dbSNP identified addi-
tional unique nonsynonymous changes and a frameshift
of HCFC1 of unknown frequency. Although many of these
variants are predicted to be damaging (Piton et al.19 and
data not shown), their functional effect has not been
tested. All six amino acid positions are highly conserved
across multiple species (Figure S10). All together, the
combined data strongly suggest that mutations of HCFC1
lead to different neurological phenotypes, which include
but are not restricted to intellectual disability.
There are several lines of evidence that implicate HCFC1
in biological processes important for normal neuronal
function and development. HCFC1 was first identified as
a crucial VP-16/Oct-1-interacting cell-proliferation factor
involved in herpes simplex virus infection (for review,
see Wysocka and Herr32). Since then, HCFC1 has been
shown to be involved with many other proteins in regu-
lating gene transcription. Among others, HCFC1 recruits
mixed-lineage leukemia (MLL, encoded by MLL [MIM
159555]) and Set-1 histone H3 lysine 4 methyltransferases
to E2F responsive promoters and induces histone methyl-
ation and transcriptional activation.17 HCFC1 has also
been implicated with other known chromatin-modifying
proteins that are known to be involved in the pathology
of intellectual disability. For example, a protein complex
containing the histone lysine demethylase PHF8 (encoded
by PHF8 [MIM 300560]) and another protein, ZNF71133
(encoded by ZNF711 [MIM 314990]), known to be impli-
cated in XLID when mutated, remove the repressivean Journal of Human Genetics 91, 694–702, October 5, 2012 699
H4K20me1 mark from the promoters of a subset of
HCFC1-E2F1-regulated genes.34 Some of the known targets
of this complex are also other genes with known muta-
tions associated with XLID; one such gene is KDM5C
(MIM 314690), which encodes another histone H3 lysine
4 demethylase (also known as JARID1C).33,35 HCFC1
directly associates with YY1,36 and through the interaction
of YY1 with MECP2, it regulates mitochondrial adenine
nucleotide translocase ANT137 (MIM 103220) and thus
might contribute to the pathology of Rett syndrome
(MIM 312750). Our microarray data on cells from affected
MRX3 family members overexpressing HCFC1 further
support the role of HCFC1 in mitochondrial function or
biogenesis. The crucial role of HCFC1 in cell-cycle regula-
tion and particularly in cell growth is supported by its
interaction with the deubiquitinating enzyme BAP136
(encoded by BAP1 [MIM 603089]), recently implicated in
various human cancers.38,39
The role of HCFC1 in neuronal cells is yet to be under-
stood despite its high expression during embryonic brain
development.20,40 We investigated HCFC1 overexpression,
as observed in affected individuals from the MRX3 family,
in embryonic neural cell types. In NSCs, overexpression
resulted in cell-cycle exit coupled with the production of
astrocytes. As implicated by others, our finding identifies
HCFC1 as a regulator of stem cell behavior.28,41,42 Studies
of HCFC1 in cell-cycle regulation have revealed require-
ments during M-phase43 and G0/G1-S phase progres-
sion.17,44 In static cell-culture models, HCFC1 is known to
promote S-phase initiation;17 however, evidence has also
suggested that mutated HCFC1 can promote G0/G1 arrest.
For example, during G0/G1, HCFC1 is known to occupy
and repress promoters of S-phase genes by bridging interac-
tions between the E2F4 (encoded by E2F4 [MIM 600659])
transcription factor and the Sin3 histone deacetylase,
thus inhibiting S-phase initiation.17 HCFC1 is also a key
transcriptional coactivator of the retinoblastoma protein
(Rb, encoded by Rb1 [MIM 614041]), a potent inhibitor
of S-phase genes.45 During muscle cell differentiation,
this regulation is required for the cell-cycle exit of
myoblasts and terminal differentiation into myotubes.45
Finally, loss-of-function studies of the HCFC1 antagonist
PDCD246 (encoded by PDCD2 [MIM 600866]) implicate
HCFC1 activity as a negative regulator of embryonic stem
cell maintenance.42 The above evidence suggests that the
effect that HCFC1 has on the cell cycle is likely to be depen-
dent on the cellular context; this is consistent with its
ability to interact with multiple transcription factors and
opposing histone modifiers in a pleiotropic manner.
We extended our studies beyond the roles of HCFC1
in NSCs to include postmitotic hippocampal neurons.
Neurons overexpressing HCFC1 displayed significant
reductions in neurite growth and viability. The reduction
in viability might be a result of increased apoptosis. Dereg-
ulation of the complex containing HCFC1, the MLL
histone methyltransferase, and E2F1 (encoded by E2F1
[MIM 189971]), which normally governs the transition700 The American Journal of Human Genetics 91, 694–702, Octoberfrom the G1-S phase of the cell cycle, is known to cause
both DNA damage and orchestrate an ensuing apoptotic
process.47 Alternatively, other cellular insults mediated
by global deregulation of gene expression might affect
neuronal cell viability. For example, consistent with ChIP
studies,28 our microarray studies using cell lines from
affected MRX3 family members identify mitochondrial
function, which is known to impact neuronal viability, as
a prominent process regulated by HCFC1.
Massively parallel sequencing is revolutionizing the
annotation of human DNA variation and thus leads to
a dramatic shift in the understanding of the genetic archi-
tecture of human traits and heritable disorders in partic-
ular. Although the recent successes are heavily biased
toward the discovery of disease-associated variation in
coding exonic regions of the human genome,5 our work
demonstrates that mutations outside these regions can
and should also be tackled.
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Note Added in Proof
During the publication of this work, a most likely patho-
genic mutation in ARID1B was identified in the simplex
case D147 and might explain his phenotype.5, 2012
